Can Boston Scientific’s Cost-Cutting Reset Halt the Slide?
Boston Scientific shares have plunged from their September 2025 highs and face another pivotal earnings release tomorrow. Management’s board-approved restructuring targets $700M–$800M in charges to yield roughly $500M of annual savings by 2029, but WATCHMAN sales headwinds and an FDA notice on a separate device complicate the outlook. Wall Street r…